Answers are grounded in this paper and cite their sources.
A new dosage form designed to provide parenteral drug delivery over a prolonged period of time following a standard injection has been investigated using testosterone as the model drug. The drug carrier consists of a biodegradable, biocompatible polymer in which the drug is dispersed on a molecular level. The polymer itself is formulated as a pseudolatex with high solid content (40.0%). The formulation has a low viscosity (97 cps) which can be injected easily through a hypodermic needle. The histopathology study showed good tissue compatibility of the pseudolatices and in-vivo tests on rats confirmed a prolonged release of drug over a 14 day period. The stability of the biodegradable poly-d, l-lactic acid latex was found not to be significantly changed over 120 days of storage at room temperature (25°). A six month study showed a slight increase (10%) in the viscosity of the parenteral product when stored at room temperature. The increase was attributed to partial coalescence of the polymer particles which had an initial diameter of 0.45 μm.
No takes yet. Share an insight, caveat, or question.
Gurny et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: